-
公开(公告)号:EP1667989A4
公开(公告)日:2008-08-20
申请号:EP04785303
申请日:2004-09-29
Applicant: PORTOLA PHARM INC
Inventor: SCARBOROUGH ROBERT M , KANE-MAGUIRE KIM A , MARLOWE CHARLES K , SMYTH MARK S , ZHANG XIAOMING
IPC: C07D401/02 , A61K31/47 , A61K31/4709 , A61K31/506 , C07D217/24 , C07D401/04 , C07D409/12
CPC classification number: C07D409/14 , C07D217/24 , C07D401/04 , C07D409/12
-
公开(公告)号:DE60238086D1
公开(公告)日:2010-12-02
申请号:DE60238086
申请日:2002-07-25
Applicant: PORTOLA PHARM INC
Inventor: SCARBOROUGH ROBERT M , JANTZEN HANS-MICHAEL , HUANG WOLIN , SEDLOCK DAVID M , MARLOWE CHARLES K , KANE-MAGUIRE KIM A
IPC: C07D239/96 , C07D409/14 , A61K31/16 , A61K31/175 , A61K31/381 , A61K31/4035 , A61K31/4196 , A61K31/4725 , A61K31/519 , A61K31/54 , A61K31/64 , A61P7/02 , A61P9/00 , A61P9/04 , A61P9/10 , A61P9/14 , A61P43/00 , C07D209/48 , C07D213/70 , C07D239/22 , C07D239/50 , C07D333/34 , C07D401/04 , C07D401/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D487/04 , C07D495/04 , C07D521/00
-
公开(公告)号:AU2004279809B2
公开(公告)日:2010-07-15
申请号:AU2004279809
申请日:2004-09-29
Applicant: PORTOLA PHARM INC
Inventor: MARLOWE CHARLES K , SMYTH MARK S , KANE-MAGUIRE KIM A , ZHANG XIAOMING , SCARBOROUGH ROBERT M
IPC: C07D217/24 , A61K31/17 , A61K31/381 , A61K31/435 , A61K31/4709 , A61K31/506 , A61P9/00 , A61P9/10 , C07D401/04 , C07D409/12
Abstract: Isoquinolinone compounds are provided that are useful for the inhibition of ADP-platelet aggregation, particularly in the treatment of thrombosis and thrombosis related conditions or disorders.
-
公开(公告)号:HK1096088A1
公开(公告)日:2007-05-25
申请号:HK07102667
申请日:2004-09-10
Applicant: PORTOLA PHARM INC
Inventor: SCARBOROUGH ROBERT M , JANTZEN HANS-MICHAEL , HUANG WOLIN , SEDLOCK DAVID M , MARLOWE CHARLES K , KANE-MAGUIRE KIM A
IPC: C07D239/96 , A61K20060101 , A61K31/16 , A61K31/175 , A61K31/381 , A61K31/4196 , A61K31/4725 , A61K31/519 , A61K31/54 , A61K31/64 , A61P20060101 , A61P7/02 , A61P9/00 , A61P9/04 , A61P9/10 , A61P9/14 , A61P43/00 , C07D20060101 , C07D209/48 , C07D213/70 , C07D239/22 , C07D239/50 , C07D333/34 , C07D401/04 , C07D401/12 , C07D405/12 , C07D409/12 , C07D409/14 , C07D417/12 , C07D487/04 , C07D495/04 , C07D521/00
Abstract: Novel compounds of formulae (I), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also relates to the use of an effective amount of a compound of formulae (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a pharmaceutical composition for preventing or treating thrombosis in a mammal.
-
公开(公告)号:ES2272742T3
公开(公告)日:2007-05-01
申请号:ES02750339
申请日:2002-07-25
Applicant: PORTOLA PHARM INC
Inventor: SCARBOROUGH ROBERT M , JANTZEN HANS-MICHAEL , HUANG WOLIN , SEDLOCK DAVID M , MARLOWE CHARLES K , KANE-MAGUIRE KIM A
IPC: C07D239/96 , C07D521/00 , A61K31/16 , A61K31/175 , A61K31/381 , A61K31/4035 , A61K31/4196 , A61K31/4725 , A61K31/519 , A61K31/54 , A61K31/64 , A61P7/02 , A61P9/00 , A61P9/04 , A61P9/10 , A61P9/14 , A61P43/00 , C07D209/48 , C07D213/70 , C07D239/22 , C07D239/50 , C07D333/34 , C07D401/04 , C07D401/12 , C07D405/12 , C07D409/12 , C07D409/14 , C07D417/12 , C07D487/04 , C07D495/04
Abstract: Un compuesto de fórmula (I): en la que: A se selecciona del grupo constituido por arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, arilalquilo, y alquilheteroarilo. W se selecciona del grupo constituido por arilo, arilo sustituido, heteroarilo, y heteroarilo sustituido. E se selecciona del grupo constituido por H, alquilo C1-C8, polihaloalquilo, cicloalquilo C3-8, arilo, arilalquilo, arilo sustituido, heteroarilo, y heteroarilo sustituido. D es en la que: n es un número entero de 0-4, Q es independientemente C o N, en la que cuando Q es un átomo de carbono anular, cada átomo de carbono anular está sustituido independientemente por X, en la que X es en cada caso un miembro seleccionado independientemente del grupo constituido por: H, halógeno, polihaloalquilo, ¿OR3, ¿SR3, ¿CN, ¿NO2, ¿SO2R3, alquilo C1-10, cicloalquilo C3-8, arilo, arilo sustituido por 1-4 grupos R3, amino, aminoalquilo C1-8, acilamino C1-3, acilamino C1-3-alquilo C1-8, alquilamino C1-6, alquilamino-C1-6-alquiloC1-8, dialquilamino C1-6, dialquilamino-C1-6-alquilo C1- 8, alcoxi C1-6, alcoxi C1-6-alquilo C1-6, carboxialquilo C1-6, alcoxi-C1-3-carbonilo, alcoxi-C1-3-carbonilalquilo C1-6, carboxialquiloxi C1-6, hidroxi, hidroxialquilo C1- 6, y un sistema anular heterocíclico de 5 a 10 miembros fusionado o no fusionado, aromático o no aromático, que tiene de 1 a 4 heteroátomos seleccionados independientemente entre N, O, y S, con la condición de que los átomos de carbono y nitrógeno, cuando estén presentes en el sistema anular heterocíclico, estén sin sustituir, mono- o di-sustituidos independientemente con 0-2 grupos R4, en la que R3 y R4 cada uno se selecciona independientemente del grupo constituido por: H, halógeno, ¿CN, ¿NO2, alquilo C1-10, cicloalquilo C3-8, arilo, amino, aminoalquilo C1-8, acilamino C1-3, acilamino C1-3-alquilo C1-8, alquilamino C1-6, alquilamino-C1-6-alquilo C1-8, dialquilamino C1-6, dialquilamino-C1-6-alquilo C1- 8, alcoxi C1-6, alcoxi C1-6-alquilo C1-6, carboxialquilo C1-6, alcoxi-C1-3-carbonilo, alcoxi-C1-3-carbonilalquilo C1-6, carboxialquiloxi C1-6, hidroxi, hidroxialquilo C1- 6, -tio y tio-alquilo C1-6; e Y se selecciona del grupo constituido por O, S, N¿OR5, y NR5, en las que R5 se selecciona del grupo constituido por: H, alquilo C1-10, cicloalquilo C3-8, NR2, y CN; o sales farmacéuticamente aceptables.
-
公开(公告)号:AU2004279809A1
公开(公告)日:2005-04-21
申请号:AU2004279809
申请日:2004-09-29
Applicant: PORTOLA PHARM INC
Inventor: MARLOWE CHARLES K , SMYTH MARK S , KANE-MAGUIRE KIM A , ZHANG XIAOMING , SCARBOROUGH ROBERT M
IPC: C07D401/02 , A61K31/47 , A61K31/4709 , A61K31/506 , C07D217/24 , C07D401/04 , C07D409/12
Abstract: Isoquinolinone compounds are provided that are useful for the inhibition of ADP-platelet aggregation, particularly in the treatment of thrombosis and thrombosis related conditions or disorders.
-
公开(公告)号:HK1064099A1
公开(公告)日:2005-01-21
申请号:HK04106901
申请日:2004-09-10
Applicant: PORTOLA PHARM INC
Inventor: SCARBOROUGH ROBERT M , JANTZEN HANS-MICHAEL , HUANG WOLIN , SEDLOCK DAVID M , MARLOWE CHARLES K , KANE-MAGUIRE KIM A
IPC: C07D20060101 , C07D239/96 , A61K20060101 , A61K31/16 , A61K31/175 , A61K31/381 , A61K31/4196 , A61K31/4725 , A61K31/519 , A61K31/54 , A61K31/64 , A61P20060101 , A61P7/02 , A61P9/00 , A61P9/04 , A61P9/10 , A61P9/14 , A61P43/00 , C07D209/48 , C07D213/70 , C07D239/22 , C07D239/50 , C07D333/34 , C07D401/04 , C07D401/12 , C07D405/12 , C07D409/12 , C07D409/14 , C07D417/12 , C07D487/04 , C07D495/04 , C07D521/00
Abstract: Novel compounds of formulae (I), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also relates to the use of an effective amount of a compound of formulae (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a pharmaceutical composition for preventing or treating thrombosis in a mammal.
-
公开(公告)号:PT1734041E
公开(公告)日:2011-01-25
申请号:PT06015189
申请日:2002-07-25
Applicant: PORTOLA PHARM INC
Inventor: HUANG WOLIN , SCARBOROUGH ROBERT M , JANTZEN HANS-MICHAEL , SEDLOCK DAVID M , MARLOWE CHARLES K , KANE-MAGUIRE KIM A
IPC: C07D239/96 , C07D409/14 , A61K31/16 , A61K31/175 , A61K31/381 , A61K31/4035 , A61K31/4196 , A61K31/4725 , A61K31/519 , A61K31/54 , A61K31/64 , A61P7/02 , A61P9/00 , A61P9/04 , A61P9/10 , A61P9/14 , A61P43/00 , C07D209/48 , C07D213/70 , C07D239/22 , C07D239/50 , C07D333/34 , C07D401/04 , C07D401/12 , C07D405/12 , C07D409/12 , C07D417/12 , C07D487/04 , C07D495/04 , C07D521/00
-
公开(公告)号:AU2001236644B8
公开(公告)日:2006-07-06
申请号:AU2001236644
申请日:2001-02-05
Applicant: PORTOLA PHARM INC
Inventor: JANTZEN HANS-MICHAEL , SEDLOCK DAVID M , HUANG WOLIN , SCARBOROUGH ROBERT M , MARLOWE CHARLES K
IPC: C07D239/48 , C07D417/12 , A61K31/381 , A61K31/4035 , A61K31/4365 , A61K31/443 , A61K31/4436 , A61K31/4439 , A61K31/497 , A61K31/501 , A61K31/506 , A61P7/02 , A61P9/00 , A61P9/10 , A61P43/00 , C07D239/22 , C07D239/50 , C07D333/34 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D495/04
Abstract: Novel compounds of formula (I) to (VI), which more particularly include sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives which are effective platelet ADP receptor inhibitors. These derivatives may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also relates to a method for preventing or treating thrombosis in a mammal comprising the step of administering a therapeutically effective amount of a compound of formulae (I)-(VI), or a pharmaceutically acceptable salt thereof.
-
公开(公告)号:ES2252193T3
公开(公告)日:2006-05-16
申请号:ES01908817
申请日:2001-02-05
Applicant: PORTOLA PHARM INC
Inventor: SCARBOROUGH ROBERT M , JANTZEN HANS-MICHAEL , HUANG WOLIN , SEDLOCK DAVID M , MARLOWE CHARLES K
IPC: C07D239/48 , A61K31/381 , A61K31/4035 , A61K31/4365 , A61K31/443 , A61K31/4436 , A61K31/4439 , A61K31/497 , A61K31/501 , A61K31/506 , A61P7/02 , A61P9/00 , A61P9/10 , A61P43/00 , C07D239/22 , C07D239/50 , C07D333/34 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D417/12 , C07D495/04 , C07D411/12 , C07D417/14 , A61K31/40 , A61K31/38 , A61K31/44 , A61K31/495 , A61K31/425 , A61K31/55 , C07D521/00
Abstract: Un compuesto de fórmula (I): en la que: y A se selecciona entre el grupo constituido por un 2-tienilo sustituido, y un 2-tienilo no sustituido en la que A opcionalmente tiene de uno a tres sustituyentes seleccionados independientemente entre el grupo constituido por alcoxi C1-6, alquilo C1-6, alquil C16 amino, hidroxi, halógeno, ciano, hidroxilo, mercapto, nitro, tioalcoxi, carboxaldehído, carboxilo, carboalcoxi, y carboxamida; W es fenileno, opcionalmente teniendo entre uno y tres sustituyentes seleccionados independientemente entre el grupo constituido por metilo, metoxi hidroxi, halógeno, ciano, hidroxilo, mercapto, nitro, tioalcoxi, carboxaldehído, carboxilo, carboalcoxi, y carboxamida; en la que: R1 se selecciona entre el grupo constituido por: H, alquilo C1-C8, polihaloalquilo, -cicloalquil C C3-8, arilo, alqilarilo, heteroarilo, -(C=O)-alquilo C1-C8, -(C=O)-arilo y -(C=O)-heteroarilo; R2, R3, R4 y R5 son cada uno de ellos miembros seleccionados independientemente entre el grupo constituido por: hidrógeno, halógeno, polihaloalquilo, -OR6, -SR6, -CN, -NO2, -SO2R6, -alquilo C1-10, -cicloalquilo C3-8, arilo, arilo sustituido con 1-4 grupos R6, amino, amino alquilo-C1-88, acil C1-3 amino, acil C1-3 amino-alquilo C1-8, alquil C1-6 amino; alquil C1-6 amino alquilo C1, 8, dialquil C1-6 amino, dialquil C1-6 amino alquilo C1, 8, alcoxi C1-6, alcoxi C1-6 alquilo C1-6, carboxi alquilo C1-6, alcoxi C1-3 carbonilo, alcoxi C1-3 carbonil-alquilo C C1-6, carboxi alquil C1-6 oxi, hidroxi, hidroxi alquilo C1-6, y un sistema de anillo heterocíclico aromático o no aromático condensado o no condensado de 5 a 10 miembros, que tiene 1 a 4 heteroátomos seleccionados independientemente entre N, O, y S, con la condición de que los átomos de carbono y nitrógeno, cuando están presentes en el sistema de anillo heterocíclico, están no sustituidos, mono- o di-sustituidos independientemente con 0-2 grupos R7; en la que R6 y R7 se seleccionan cada uno de ellos independientemente entre el grupo constituido por: hidrógeno, halógeno, -CN, -NO2, -alquilo C1-10, -cicloalquilo C3-8, arilo, amino, amino -alquilo C1-8, acil C1-3 amino, acil C1-3 amino-alquilo C1-8, alquil C1-6 amino; alquil C1-6 amino alquilo C1, 8, dialquil C1-6 amino, dialquil C1-6 amino alquilo C1, 8, alcoxi C1-6, alcoxi C1-6 alquilo C1-6, carboxi-alquilo C1-6, alcoxi C1-3 carbonilo, alcoxi C1-3 carbonil-alquiloC1-6, carboxi alquil C1-6 oxi, hidroxi, hidroxi alquilo C1-6, -tio y tio-alquilo C1-6; Y se selecciona entre el grupo constituido por O, S, N-OR8; NR8; en la que R8 se selecciona entre el grupo constituido por: H, alquilo C1~10; cicloalquilo C3-8 y CN; y las sales y profármacos farmacéuticamente aceptables de los mismos.
-
-
-
-
-
-
-
-
-